Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
PR

NASDAQ · PRPO

Precipio, Inc.

Healthcare · Medical - Diagnostics & Research

$23.50

Up+$0.29 (+1.25%)

Updated Aug 15, 2026, 4:15 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
37.66M
P/E ratio
-31.99
Dividend yield
0.00%
52-week range
$19.22 – $33.63
Volume
75.81K
Avg. volume
15.04K

Price performance

PRPO price history

1M range · 21 trading sessions · Daily adjusted prices

PRPO closed at $23.50 after 21 trading sessions, down 4.63% for the selected period.

Last close
$23.50
Period change
-4.63%
Period low
$21.19
Period high
$24.64
Daily close
View OHLC price history
PRPO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 14, 2026$23.24$24.48$22.52$23.5075.81K
Aug 13, 2026$22.89$23.415$22.23$23.21411.28K
Aug 12, 2026$23.01$23.02$21.48$22.5486.46K
Aug 11, 2026$22.65$23.555$21.76$22.3561.49K
Aug 10, 2026$23.76$24.245$22.60$22.60246.85K
Aug 7, 2026$23.49$25.04$23.335$23.9762.78K
Aug 6, 2026$23.72$23.72$22.60$23.4642.26K
Aug 5, 2026$22.75$23.60$22.6075$23.485.18K
Aug 4, 2026$22.46$22.77$21.85$22.7532.86K
Aug 3, 2026$21.64$23.335$21.50$22.13113.18K
Jul 31, 2026$21.19$21.65$20.20$21.6521.13K
Jul 30, 2026$22.10$22.50$19.22$21.19149K
Jul 29, 2026$22.67$23.30$21.58$21.85117.56K
Jul 28, 2026$22.92$23.59$22.51$22.6786.16K
Jul 27, 2026$23.76$24.10$22.55$22.92187.18K
Jul 24, 2026$22.89$23.915$22.50$23.6838.48K
Jul 23, 2026$23.70$23.73$22.51$22.8894.41K
Jul 22, 2026$24.50$24.75$22.57$23.48254.92K
Jul 21, 2026$23.25$24.55$22.95$23.7085.15K
Jul 20, 2026$24.40$24.70$22.80$23.40109.13K
Jul 17, 2026$23.68$24.64$23.10$24.64108.32K

Latest PRPO news

The latest Smart Investors Daily articles mentioning PRPO.

Stock researchCompany · Overview

PRPO research

Overview

Company profile and research snapshot.

Company profile

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
PRPO recent ratings
DateFirmRatingTarget
Nov 22, 2019Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 31, 2026

Precipio Announces Q2-2026 Shareholder Update Call

Conference Call will be held on August 17th, 2026, at 5:00 PM EDTNEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. “We are excited to share our upcoming results for Q2. The team continues to mak

defenseworld.net · Dec 10, 2025

Privia Health Group (NASDAQ:PRVA) vs. Precipio (NASDAQ:PRPO) Critical Contrast

Precipio (NASDAQ: PRPO - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings. Risk and Volatility Precipio has a beta of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By